![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Biogen’s and Eisai’s Alzheimer’s Therapy Grabs FDA Priority Review
Biogen’s and Eisai’s Alzheimer’s Therapy Grabs FDA Priority Review
August 10, 2020
The FDA has granted Biogen’s and Eisai’s investigational Alzheimer’s treatment aducanumab a priority review.
The drug’s approval would make aducanumab the first therapy to reduce clinical decline in Alzheimer’s patients and the first to show that removing amyloid beta improves clinical outcomes.
The agency is expected to issue a decision on the drug’s approval by March 7, 2021.
Upcoming Events
-
21Oct